Business Context and Reporting Period
Cormedix Inc. (CorMedix) filed this Form 8-K on August 31, 2011, reporting the entry into a Material Definitive Agreement. The filing details Amendment No. 3 to a Contribution Agreement with Shiva Biomedical, LLC, originally dated July 26, 2006.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The only specific financial figures disclosed relate to the new agreement obligations:
- Upfront Payment: $100,000 payable to Shiva Biomedical on or before September 8, 2011.
- Additional Payments: $450,000 total, payable in installments on or about December 31, 2011, and March 31, 2012.
- Security Interest: CorMedix granted Shiva a first security interest in the Company's IP Rights, with a Security Agreement to be executed by October 1, 2011.
Material Changes
The Amendment introduces several material changes to the existing Contribution Agreement:
- Timeline Extension: The deadline to initiate patient dosing in a "Pivotal Trial" for a License Product is extended to March 31, 2012.
- Termination Rights: If the Pivotal Trial is not initiated by the new deadline, Shiva retains the right to terminate the Agreement within 15 days of written notice.
- Governance: A "Development Committee" (two CorMedix reps, one Shiva rep) is established to oversee development. CorMedix holds sole and final decision-making authority if the committee cannot reach unanimity.
- Discontinuation Rights: CorMedix may discontinue development of License Products (Shiva 101/CRMD0002 or Shiva 102/CRMD0001) at its sole discretion. In such an event, CorMedix must grant Shiva an irrevocable, fully paid-up, non-exclusive unblocking license under relevant IP.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The filing indicates a strategic shift to extend development timelines and clarify decision-making authority regarding clinical trials. A press release announcing the execution was issued on September 6, 2011.
Risks and Contingencies:
- Termination Risk: Failure to meet the March 31, 2012, dosing deadline exposes the Company to immediate termination of the agreement by Shiva.
- Liquidity Impact: The Company faces immediate cash outflows totaling $550,000 over the next six months to satisfy payment obligations under the Amendment.
- IP Encumbrance: The grant of a first security interest in Company IP Rights limits the Company's ability to leverage these assets for other financing without Shiva's consent.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the $100,000 payment due September 8, 2011, and subsequent $450,000 obligations.
- Confirm the status of the Security Agreement regarding the IP Rights, which is required to be executed by October 1, 2011.
- Monitor the Company's progress toward initiating a Pivotal Trial by the March 31, 2012, deadline to avoid termination of the Shiva agreement.
- Review the specific definitions of "Pivotal Trial" and "License Product" in the full Agreement to understand the scope of the development obligations.